Review of NICE Technology Appraisal Guidance No. 213; Aripiprazole for schizophrenia in people aged 15 to 17 years

TA213; Aripiprazole for schizophrenia in people aged 15 to 17 years was published in January 2011.  We recently became aware of a potential overlap with a clinical guideline, and as such, this has prompted the Institute to re-look at the existing guidance and the possible scope for a review.

We believe that this topic would be better dealt with within the context of a clinical guideline. Consequently we propose that the review of the original guidance be incorporated into the on-going NICE guideline on Schizophrenia: recognition and management of schizophrenia presenting up to 18 years of age, which is currently in development.

TA213 will remain in existence alongside the clinical guideline and will be moved to the static guidance list. This proposal will have the consequence of preserving the funding direction that is linked to the technology appraisal.

In order to be completely confident that this is appropriate, we are asking all relevant consultees and commentators, to inform us of any evidence which will help us decide the best way to update this guidance. Please see appendix A for a full list of the organisations we have contacted. 

May 2011